血液科指南

订阅

MedSci主页 / 所有栏目 / 血液科指南

2018 专家共识：儿童接受嵌合抗原受体T细胞治疗管理指南

2018-08-02 国外血液科相关专家小组 Nature Reviews Clinical Oncology.Aug 2018.

:嵌合抗原受体T细胞治疗基因治疗

2017年，嵌合抗原受体（CAR）T细胞治疗儿童和青少年复发性和/或难治性CD19+的急性淋巴细胞白血病患者，成果美国首个获批的基因疗法。本文主要针对儿童接受CAR-T细胞治疗的相关内容提供指导建议。

中文标题：

2018 专家共识：儿童接受嵌合抗原受体T细胞治疗管理指南

英文标题：

Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy

发布机构：

国外血液科相关专家小组

发布日期：

2018-08-02

简要介绍：

2017年，嵌合抗原受体（CAR）T细胞治疗儿童和青少年复发性和/或难治性CD19+的急性淋巴细胞白血病患者，成果美国首个获批的基因疗法。本文主要针对儿童接受CAR-T细胞治疗的相关内容提供指导建议。 

拓展指南：与T细胞相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 专家共识：儿童接受嵌合抗原受体T细胞治疗管理指南)] GetToolGuiderByIdResponse(projectId=1, id=d4d8e1c0016262fa, title=2018 专家共识：儿童接受嵌合抗原受体T细胞治疗管理指南, enTitle=Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy, guiderFrom=Nature Reviews Clinical Oncology.Aug 2018., authorId=null, author=, summary=2017年，嵌合抗原受体（CAR）T细胞治疗儿童和青少年复发性和/或难治性CD19+的急性淋巴细胞白血病患者，成果美国首个获批的基因疗法。本文主要针对儿童接受CAR-T细胞治疗的相关内容提供指导建议。 , cover=, journalId=null, articlesId=null, associationId=971, associationName=国外血液科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Thu Aug 02 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>2017年，嵌合抗原受体（CAR）T细胞治疗儿童和青少年复发性和/或难治性CD19+的急性淋巴细胞白血病患者，成果美国首个获批的基因疗法。本文主要针对儿童接受CAR-T细胞治疗的相关内容提供指导建议。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>T细胞</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=a5cb91c001592ae7" title="NCCN临床实践指南：T细胞淋巴瘤（2018.V4）" target=_blank>NCCN临床实践指南：T细胞淋巴瘤（2018.V4）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=356181c001563a38" title="NCCN临床实践指南：T细胞淋巴瘤（2018.V3）" target=_blank>NCCN临床实践指南：T细胞淋巴瘤（2018.V3）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=bb2931c001539ab6" title="NCCN临床实践指南：T细胞淋巴瘤（2018.V2）" target=_blank>NCCN临床实践指南：T细胞淋巴瘤（2018.V2）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=8681a1c001520376" title="NCCN临床实践指南：T细胞淋巴瘤（2018.V1）" target=_blank>NCCN临床实践指南：T细胞淋巴瘤（2018.V1）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=32b2b1c001382847" title="NCCN临床实践指南：T细胞淋巴瘤（2017.V2）" target=_blank>NCCN临床实践指南：T细胞淋巴瘤（2017.V2）</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=T%E7%BB%86%E8%83%9E" target=_blank>有关T细胞更多指南</a></ul>, tagList=[TagDto(tagId=70530, tagName=:), TagDto(tagId=79037, tagName=嵌合抗原受体T细胞治疗), TagDto(tagId=1542, tagName=基因治疗)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4667, appHits=52, showAppHits=0, pcHits=2911, showPcHits=2407, likes=99, shares=2, comments=6, approvalStatus=1, publishedTime=Sat Aug 11 23:04:28 CST 2018, publishedTimeString=2018-08-02, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Aug 11 23:04:28 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 22:48:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 专家共识：儿童接受嵌合抗原受体T细胞治疗管理指南)])
2018 专家共识：儿童接受嵌合抗原受体T细胞治疗管理指南
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1052001, encodeId=4be41052001c0, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Thu Sep 16 15:32:03 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338218, encodeId=de81338218f0, content=了解一下谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:13:04 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338167, encodeId=ca9733816e2a, content=谢谢分享，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sun Aug 12 16:57:46 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338073, encodeId=1d623380e3cb, content=学习了！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Aug 12 07:19:31 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338064, encodeId=1d973380649b, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Aug 12 06:50:03 CST 2018, time=2018-08-12, status=1, ipAttribution=)]
    2021-09-16 H8888888

    受益匪浅

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1052001, encodeId=4be41052001c0, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Thu Sep 16 15:32:03 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338218, encodeId=de81338218f0, content=了解一下谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:13:04 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338167, encodeId=ca9733816e2a, content=谢谢分享，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sun Aug 12 16:57:46 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338073, encodeId=1d623380e3cb, content=学习了！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Aug 12 07:19:31 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338064, encodeId=1d973380649b, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Aug 12 06:50:03 CST 2018, time=2018-08-12, status=1, ipAttribution=)]
    2018-08-13 kafei

    了解一下谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1052001, encodeId=4be41052001c0, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Thu Sep 16 15:32:03 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338218, encodeId=de81338218f0, content=了解一下谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:13:04 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338167, encodeId=ca9733816e2a, content=谢谢分享，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sun Aug 12 16:57:46 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338073, encodeId=1d623380e3cb, content=学习了！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Aug 12 07:19:31 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338064, encodeId=1d973380649b, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Aug 12 06:50:03 CST 2018, time=2018-08-12, status=1, ipAttribution=)]
    2018-08-12 liumin1987

    谢谢分享，学习了。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1052001, encodeId=4be41052001c0, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Thu Sep 16 15:32:03 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338218, encodeId=de81338218f0, content=了解一下谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:13:04 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338167, encodeId=ca9733816e2a, content=谢谢分享，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sun Aug 12 16:57:46 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338073, encodeId=1d623380e3cb, content=学习了！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Aug 12 07:19:31 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338064, encodeId=1d973380649b, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Aug 12 06:50:03 CST 2018, time=2018-08-12, status=1, ipAttribution=)]
    2018-08-12 zb1235672

    学习了！！！！！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1052001, encodeId=4be41052001c0, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Thu Sep 16 15:32:03 CST 2021, time=2021-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338218, encodeId=de81338218f0, content=了解一下谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Aug 13 00:13:04 CST 2018, time=2018-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338167, encodeId=ca9733816e2a, content=谢谢分享，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Sun Aug 12 16:57:46 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338073, encodeId=1d623380e3cb, content=学习了！！！！！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Sun Aug 12 07:19:31 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338064, encodeId=1d973380649b, content=阅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/09/07/a9772c74ffd6edc03a7f9af07b4747f6.jpg, createdBy=b3722138742, createdName=sunfeifeiyang, createdTime=Sun Aug 12 06:50:03 CST 2018, time=2018-08-12, status=1, ipAttribution=)]
    2018-08-12 sunfeifeiyang

    阅

    0

相关指南

抗体偶联药物质量控制和临床前评价专家共识

中国药学相关专家小组（统称） · 2018-07-30

2018 TES临床实践指南：睾酮治疗男性性腺功能减退

美国内分泌学会(TES,The Endocrine Society) · 2018-03-17

2017 ESCMID/ECMM/ERS指南：曲霉菌病的诊断和管理

欧洲临床微生物与感染性疾病学会(ESCMID,European Society of Clinical Microbiology and Infectious Diseases) · 2018-03-12

我国青光眼临床诊断和治疗描述性术语专家建议（2018年）

中华医学会眼科学分会青光眼学组 · 2018-03-10

醋酸钠林格液围手术期临床应用专家共识

中国临床麻醉/疼痛相关专家组（统称） · 2018-02-01

加拿大妇产科医师学会《妊娠期单纯疱疹病毒的管理指南》2017版解读

暂未更新 · 2017-12-15